Analysts expect The Beauty Health Company (NASDAQ:SKIN – Get Rating) to post sales of $68.89 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Beauty Health’s earnings, with estimates ranging from $62.30 million to $73.17 million. The firm is expected to announce its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Beauty Health will report full year sales of $328.22 million for the current financial year, with estimates ranging from $325.30 million to $331.90 million. For the next year, analysts anticipate that the company will post sales of $408.07 million, with estimates ranging from $395.80 million to $428.90 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Beauty Health.
Beauty Health (NASDAQ:SKIN – Get Rating) last released its earnings results on Tuesday, February 22nd. The company reported $0.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.04. The firm had revenue of $77.90 million during the quarter, compared to analysts’ expectations of $70.90 million. The firm’s quarterly revenue was up 106.1% on a year-over-year basis.
Several analysts have recently issued reports on SKIN shares. DA Davidson boosted their price objective on shares of Beauty Health from $32.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, February 23rd. William Blair started coverage on shares of Beauty Health in a research note on Friday, January 7th. They set an “outperform” rating for the company. Benchmark boosted their price objective on shares of Beauty Health from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Monday, March 14th. JPMorgan Chase & Co. initiated coverage on shares of Beauty Health in a report on Friday, March 11th. They set an “overweight” rating and a $24.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of Beauty Health from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a report on Saturday, February 26th. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $27.90.
A number of hedge funds have recently modified their holdings of the business. Norges Bank acquired a new position in Beauty Health in the 4th quarter worth $12,923,000. Walleye Capital LLC acquired a new position in Beauty Health in the 4th quarter worth $1,083,000. Wells Fargo & Company MN lifted its holdings in Beauty Health by 436.7% in the 4th quarter. Wells Fargo & Company MN now owns 682,275 shares of the company’s stock worth $16,484,000 after buying an additional 555,158 shares in the last quarter. William Blair Investment Management LLC lifted its holdings in Beauty Health by 232.2% in the 4th quarter. William Blair Investment Management LLC now owns 6,251,906 shares of the company’s stock worth $151,046,000 after buying an additional 4,370,217 shares in the last quarter. Finally, Allianz Asset Management GmbH increased its position in shares of Beauty Health by 59.4% in the 4th quarter. Allianz Asset Management GmbH now owns 119,614 shares of the company’s stock worth $2,890,000 after purchasing an additional 44,573 shares during the last quarter. Hedge funds and other institutional investors own 62.99% of the company’s stock.
Shares of NASDAQ SKIN traded up $1.52 during trading on Tuesday, hitting $18.11. 2,950,079 shares of the company traded hands, compared to its average volume of 2,374,956. Beauty Health has a 1 year low of $9.71 and a 1 year high of $30.17. The company has a 50-day moving average price of $15.85 and a 200-day moving average price of $21.73. The company has a quick ratio of 12.63, a current ratio of 13.09 and a debt-to-equity ratio of 2.41.
About Beauty Health (Get Rating)
Edge Systems, LLC designs, develops, manufactures, markets, and sells aesthetic technologies and products. It offers hydradermabrasion system that enhances the skin to cleanse, exfoliate, extract, and hydrate simultaneously; Hydraglucan Intense Hydration Booster, a customization for the HydraFacial treatment exfoliates the skin by improving cell renewal and delivers ingredients, including hyaluronic acid, glucan, and betaine to hydrate the skin and provide anti-aging benefits; HydraFacial Daily Essentials, which provides detoxification, rejuvenation, and protection of skin; crystal microdermabrasion systems; and light emitting diode systems.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
Receive News & Ratings for Beauty Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Beauty Health and related companies with MarketBeat.com’s FREE daily email newsletter.